Coherus Oncology (CHRS) Enterprise Value (2012 - 2026)

Coherus Oncology has disclosed Enterprise Value across 15 years of filings, most recently posting -$167.0 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$167.0 million, down 102.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$167.0 million (down 102.7% YoY), and the FY2025 annual result was -$172.1 million, down 36.62% from the prior year.
• Enterprise Value came in at -$167.0 million for Q1 2026 at Coherus Oncology, up from -$172.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$82.4 million in Q1 2025 to a low of -$325.7 million in Q1 2022.
• The 5-year median for Enterprise Value is -$167.0 million (2026), against an average of -$182.1 million.
• Across the five-year window, Enterprise Value sank 102.81% in 2024 and surged 68.28% in 2025, its largest moves.
• Coherus Oncology's Enterprise Value stood at -$191.7 million in 2022, then jumped by 38.57% to -$117.7 million in 2023, then declined by 7.0% to -$126.0 million in 2024, then sank by 36.62% to -$172.1 million in 2025, then gained by 2.95% to -$167.0 million in 2026.
• The last three Enterprise Value figures came in at -$167.0 million (Q1 2026), -$172.1 million (Q4 2025), and -$191.7 million (Q3 2025), per Business Quant data.